Minerva Neurosciences, Inc. (NERV) stock
Close on Nov 12, 2026Market cap $113.64MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $113.64M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$290.86M
- EPS, diluted
- -$34.67
- Book value per share
- -$1.30
- Diluted shares
- 75M
Trading
- Next earnings
- Mar 10, 2027 (estimated, before the open)
- Previous close
- $2.56
- Open
- $2.53
- Day's range
- $2.34 – $2.53
- Volume
- 79,398
- Average volume (20 days)
- 193,642
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.41
- 52-week range
- $1.96 – $8.80
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 92.4%
- Relative volume
- 0.43×
- WACC
- 7.4%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NERV | S&P 500 | Difference | NERV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.6% | -2.7% | −15.0 pts | ||
| 3 months | -39.3% | -1.7% | −37.5 pts | ||
| Year to date | -40.8% | +11.9% | −52.7 pts | ||
| 1 year | -40.5% | +12.0% | −52.5 pts | ||
| 3 years | -42.0% | +78.2% | −120.1 pts | -16.6% | +21.2% |
| 5 years | -77.3% | +73.2% | −150.5 pts | -25.7% | +11.6% |
| 10 years | -97.8% | +309.6% | −407.4 pts | -31.7% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Minerva Neurosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Update
About Minerva Neurosciences
Pharmaceutical Preparations
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary product candidates for individuals suffering from central nervous system disorders. The company’s principal development pipeline centers on roluperidone, an investigational therapy designed to target negative symptoms in patients diagnosed with schizophrenia. As a development-stage biopharmaceutical organization, its prospective customer base encompasses healthcare providers, medical facilities, and the broader patient population requiring treatment for central nervous system indications.
Company profile, executives and historyMinerva Neurosciences stock: common questions
What is Minerva Neurosciences's stock price?
NERV closed at $2.38 on Nov 12, 2026, down 7.03% on the day. Over the past 52 weeks it traded between $1.96 and $8.80.
What is Minerva Neurosciences's market cap?
Minerva Neurosciences was worth $113.64M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NERV's P/E ratio?
Minerva Neurosciences lost money over fiscal 2025 (diluted EPS -$34.67), so it has no meaningful P/E ratio.
Does Minerva Neurosciences pay a dividend?
No. Minerva Neurosciences has not paid a cash dividend over the last twelve months.
When does Minerva Neurosciences report earnings next?
Minerva Neurosciences is expected to report Q4 FY2026 results on Mar 10, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NERV stock performed over the past year?
Including dividends, NERV returned -40.5% over the past year, against +12.0% for the S&P 500.
How many NERV shares are sold short?
2M shares were sold short at the latest FINRA report, 4.15% of the float, or 10.5 days of average trading volume.
Who are Minerva Neurosciences's competitors?
Companies most similar to Minerva Neurosciences by business, industry and size include MPLT, RVPH, RAPP, ANRO, XENE.
See a number that looks wrong?